News Breaks |
|
|
| September 24, 2012 |
| 05:38 EDT |  | NVS | Novartis: RLX030 reduced deaths in patients with acute heart failure
Novartis' Phase III study results show that investigational RLX030, or serelaxin, reduced all-cause mortality in patients with acute heart failure, or AHF. The six-month RELAX-AHF study shows that RLX030 reduces the number of deaths in patients with this disease, which has a higher mortality rate than most other cardiovascular diseases. The study will be presented at the American Heart Association, or AHA, congress in Los Angeles in November, 2012. Novartis will initiate discussions of the results of this single Phase III study with health authorities worldwide shortly. RLX030 is the first in a new class of medicines and is a recombinant form of the human hormone relaxin-2 which occurs naturally in both men and women. |
|
|
News For NVS From The Last 14 Days Check below for free stories on NVS the last two weeks. |
|
|
| May 21, 2013 |
| 07:44 EDT |  | NVS | Sachs Associates to host a forum
 Subscribe for More Information |
|
| 07:24 EDT | | NVS | Global Health Care to host a conference
Subscribe for More Information |
|
| May 20, 2013 |
| 07:29 EDT | | NVS | Deutsche Bank to host a conference
dbAccess Asia Conference 2013 is being held in Singapore on May 20-22. |
|
| May 17, 2013 |
| 16:20 EDT | | NVS | Novartis drug Afinitor extended time without disease progression in women
Subscribe for More Information |
|
| May 16, 2013 |
| 08:11 EDT | | NVS | Novartis says no intention of pursuing Actavis, Bloomberg reports
Subscribe for More Information |
|
| May 15, 2013 |
| 19:37 EDT |  | NVS | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information |
|
| 18:17 EDT | | NVS | Novartis weighs possible bid for Actavis, DJ reports
Subscribe for More Information |
|
| May 10, 2013 |
| 05:42 EDT | | NVS | Novartis drug Ilaris approved by FDA
Subscribe for More Information |
|
|
|
|
|
